NXC-201 CAR-T

PreclinicalCell therapy

NNexcella Inc.

NXC-201 CAR-T is one of 5 biologic programs targeting Light Chain (AL) Amyloidosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Light Chain (AL) AmyloidosisActive, not recruiting

Light Chain (AL) AmyloidosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Light Chain (AL) Amyloidosis

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

2 2

Etentamig

AbbVie

Phase 3

1 3

Venclexta

AbbVie

Phase 2

1 4

First-Line Dara-Borcyd Treatment

PPeking University First Hospital

Preclinical

1 5

NXC-201 CAR-T

NNexcella Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2039

PreclinicalActive, not recruiting

Light Chain (AL) Amyloidosis

NCT06097832

Clinical

Trials by Indication[1]

Light Chain (AL) Amyloidosis1 trial

Phase 1b/2 Study of NXC-201 for the Treatment of Patients With Relapsed or Refractory AL Amyloidosis

Active, not recruiting·NNexcella Inc.·Preclinical·NCT06097832·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NXC-201 CAR-T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NXC-201 CAR-T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NXC-201 CAR-T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nexcella Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Preclinical[1]
Company: NNexcella Inc.

NXC-201 CAR-T

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2039

Trials by Indication[1]

Light Chain (AL) Amyloidosis1 trial

References

Drug Info

Quick Facts

Related News